Ixico wins four new contracts worth over £3m

Brain health company Ixico was recently awarded four new contracts with “leading” pharmaceutical groups and a specialist biotechnology firm totalling over £3m in value.

The contracts involve global clinical trials of novel drugs for Alzheimer's disease spanning three major phases of drug development and are expected to run for the next two to four years, depending on whether they progress successfully through the clinical trials process.

They will use Ixico's expertise in the Alzheimer's field and its proprietary TrialTracker and Assessa digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.

Ixico said revenue from the contracts boosts its confidence of meeting market expectations.

Chief executive officer Professor Derek Hill commented: “We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of Ixico's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease.”

At 1356GMT, Ixico shares were up 7% to 31.56p.